Market Cap 834.45M
Revenue (ttm) 4.63M
Net Income (ttm) -201.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,344.28%
Debt to Equity Ratio 0.00
Volume 4,866,100
Avg Vol 3,265,940
Day's Range N/A - N/A
Shares Out 180.62M
Stochastic %K 65%
Beta 2.26
Analysts Strong Sell
Price Target $7.03

Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accum...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 465 0013
Address:
60 First Street, Cambridge, United States
LadsAndGents
LadsAndGents Jul. 9 at 10:15 PM
$PRME timely exit total in 4.60s, I want to get in if it dips bit more, at the same time they don’t have cash before next big news, could see dilution? Should I wait out ? $XBI anyone chime in?
1 · Reply
Farorm
Farorm Jul. 9 at 7:53 PM
$PRME congrats market nobody is bullish anymore!
0 · Reply
srost002
srost002 Jul. 9 at 7:35 PM
$PRME lol cant make this shit up. Xbi holding bro, wrong direction
1 · Reply
Floorguy7
Floorguy7 Jul. 9 at 6:58 PM
0 · Reply
Farorm
Farorm Jul. 9 at 6:48 PM
$PRME I smell algos hunting your stops ❤️‍🔥
1 · Reply
Floorguy7
Floorguy7 Jul. 9 at 6:01 PM
$PRME how about a quick drop to 4:20…
1 · Reply
Hopipaytrader
Hopipaytrader Jul. 9 at 4:43 PM
$PRME this one’s gonna get angry someday
0 · Reply
Floorguy7
Floorguy7 Jul. 9 at 4:12 PM
$PRME sniff sniff you smell that… opportunity
0 · Reply
PorkchopSquats
PorkchopSquats Jul. 9 at 9:33 AM
$PRME Thank you @Thelonius_Stonk for the horniness.
1 · Reply
BIOTECH_GURU
BIOTECH_GURU Jul. 9 at 3:23 AM
$TERN $ALMS $PRME $ALT $CAPR Alright folks. You saw AlMS, TERN and CApR MAKE WILD RUNS IN 8 MONTHS. get ready for the next runs. $PRME Just formed a golden cross. Won huge legal battle which had a lot of overhang and drove price from upper teens to below $3. Continues to be the highest asymetric play in gene editing as the technology is the cleanest. In human proof of concept is already proven and published. This will make those with high conviction big gains. $ALT all the waiting will be paying off within the next 6 months. $CAPR dropped back down to let me buy the dip. 60 dollars PT. Nfa Gltya.
0 · Reply
Latest News on PRME
Prime Medicine Slides: Corporate presentation

Jul 7, 2026, 7:00 AM EDT - 2 days ago

Prime Medicine Slides: Corporate presentation


Prime Medicine granted RMAT designation for PM359

2026-06-22T12:20:45.000Z - 17 days ago

Prime Medicine granted RMAT designation for PM359


Prime Medicine Transcript: AGM 2026

Jun 5, 2026, 2:00 PM EDT - 4 weeks ago

Prime Medicine Transcript: AGM 2026


Prime Medicine Slides: Corporate presentation

Jun 3, 2026, 7:00 AM EDT - 5 weeks ago

Prime Medicine Slides: Corporate presentation


Prime Medicine reports Q1 EPS (28c), consensus (25c)

2026-05-07T19:46:03.000Z - 2 months ago

Prime Medicine reports Q1 EPS (28c), consensus (25c)


Prime Medicine Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Prime Medicine Quarterly report: Q1 2026


Prime Medicine Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Prime Medicine Earnings release: Q1 2026


Prime Medicine management to meet with Oppenheimer

2026-05-07T02:02:00.000Z - 2 months ago

Prime Medicine management to meet with Oppenheimer


Prime Medicine Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Prime Medicine Proxy statement: Proxy filing


Prime Medicine Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Prime Medicine Proxy statement: Proxy filing


Prime Medicine appoints Makhni as Chief Financial Officer

2026-04-16T12:25:29.000Z - 3 months ago

Prime Medicine appoints Makhni as Chief Financial Officer


Prime Medicine initiated with an Outperform at Oppenheimer

2026-03-12T10:26:58.000Z - 4 months ago

Prime Medicine initiated with an Outperform at Oppenheimer


Prime Medicine reports FY25 EPS ($1.35) vs ($1.65) last year

2026-03-03T13:07:13.000Z - 4 months ago

Prime Medicine reports FY25 EPS ($1.35) vs ($1.65) last year


Prime Medicine Annual report: Q4 2025

Mar 3, 2026, 8:00 AM EST - 4 months ago

Prime Medicine Annual report: Q4 2025


Prime Medicine Earnings release: Q4 2025

Mar 3, 2026, 8:00 AM EST - 4 months ago

Prime Medicine Earnings release: Q4 2025


Prime Medicine Slides: Corporate presentation

Mar 2, 2026, 7:00 AM EST - 4 months ago

Prime Medicine Slides: Corporate presentation


Prime Medicine to Participate in Upcoming Investor Conferences

Feb 25, 2026, 8:00 AM EST - 4 months ago

Prime Medicine to Participate in Upcoming Investor Conferences


Prime Medicine initiated with an Outperform at LifeSci Capital

2025-12-23T13:50:25.000Z - 7 months ago

Prime Medicine initiated with an Outperform at LifeSci Capital


Prime Medicine announces NEJM publication of PM359 data

2025-12-07T18:30:05.000Z - 7 months ago

Prime Medicine announces NEJM publication of PM359 data


Prime Medicine transferred with Neutral rating at JPMorgan

2025-11-18T12:55:59.000Z - 8 months ago

Prime Medicine transferred with Neutral rating at JPMorgan


Prime Medicine Transcript: KOL Event

Nov 12, 2025, 8:00 AM EST - 8 months ago

Prime Medicine Transcript: KOL Event


Prime Medicine Press release: KOL Event

Nov 12, 2025, 8:00 AM EST - 8 months ago

Prime Medicine Press release: KOL Event


Prime Medicine Slides: KOL Event

Nov 12, 2025, 8:00 AM EST - 8 months ago

Prime Medicine Slides: KOL Event


Prime Medicine price target lowered to $4.25 from $5 at Citi

2025-11-11T11:36:03.000Z - 8 months ago

Prime Medicine price target lowered to $4.25 from $5 at Citi


Prime Medicine Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 8 months ago

Prime Medicine Quarterly report: Q3 2025


Prime Medicine Earnings release: Q3 2025

Nov 7, 2025, 7:00 AM EST - 8 months ago

Prime Medicine Earnings release: Q3 2025


Prime Medicine Slides: Corporate Presentation

Nov 6, 2025, 7:00 AM EST - 8 months ago

Prime Medicine Slides: Corporate Presentation


Prime Medicine Slides: Corporate Presentation

Sep 17, 2025, 7:00 AM EDT - 10 months ago

Prime Medicine Slides: Corporate Presentation


Prime Medicine Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Prime Medicine Quarterly report: Q2 2025


Prime Medicine Earnings release: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Prime Medicine Earnings release: Q2 2025


Prime Medicine Announces Pricing of Public Offering

Jul 30, 2025, 9:33 PM EDT - 1 year ago

Prime Medicine Announces Pricing of Public Offering


Prime Medicine Proxy statement: Proxy Filing

Jul 14, 2025, 8:00 AM EDT - 1 year ago

Prime Medicine Proxy statement: Proxy Filing


Prime Medicine Proxy statement: Proxy Filing

Jul 2, 2025, 8:00 AM EDT - 1 year ago

Prime Medicine Proxy statement: Proxy Filing


Prime Medicine Slides: Corporate Presentation

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Prime Medicine Slides: Corporate Presentation


Prime Medicine Proxy statement: Proxy Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

Prime Medicine Proxy statement: Proxy Filing


Prime Medicine Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Prime Medicine Quarterly report: Q1 2025


Prime Medicine Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Prime Medicine Earnings release: Q1 2025


Prime Medicine Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Prime Medicine Proxy statement: Proxy Filing


Prime Medicine Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Prime Medicine Proxy statement: Proxy Filing


Prime Medicine Annual report: Q4 2024

Feb 28, 2025, 8:00 AM EST - 1 year ago

Prime Medicine Annual report: Q4 2024


Prime Medicine Earnings release: Q4 2024

Feb 28, 2025, 8:00 AM EST - 1 year ago

Prime Medicine Earnings release: Q4 2024


Prime Medicine Slides: FY 2025

Jan 14, 2025, 6:00 PM EST - 1 year ago

Prime Medicine Slides: FY 2025


Prime Medicine Registration statement: Registration Filing

Dec 13, 2024, 7:00 AM EST - 1 year ago

Prime Medicine Registration statement: Registration Filing


Prime Medicine Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 1:15 PM EST - 1 year ago

Prime Medicine Transcript: Stifel 2024 Healthcare Conference


Prime Medicine Quarterly report: Q3 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Prime Medicine Quarterly report: Q3 2024


Prime Medicine Earnings release: Q3 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Prime Medicine Earnings release: Q3 2024


Prime Medicine Unveils Strategically Focused Pipeline

Sep 30, 2024, 7:01 AM EDT - 1 year ago

Prime Medicine Unveils Strategically Focused Pipeline


Prime Medicine Quarterly report: Q2 2024

Aug 8, 2024, 8:15 AM EDT - 2 years ago

Prime Medicine Quarterly report: Q2 2024


Prime Medicine Earnings release: Q2 2024

Aug 8, 2024, 8:15 AM EDT - 2 years ago

Prime Medicine Earnings release: Q2 2024


Prime Medicine Proxy statement: Proxy Filing

May 21, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine Proxy statement: Proxy Filing


Alphabet Bought Up Two Slumping Stocks

May 12, 2024, 3:00 AM EDT - 2 years ago

Alphabet Bought Up Two Slumping Stocks

GOOG GOOGL GTLB


Prime Medicine Quarterly report: Q1 2024

May 10, 2024, 7:00 AM EDT - 2 years ago

Prime Medicine Quarterly report: Q1 2024


Prime Medicine Earnings release: Q1 2024

May 10, 2024, 7:00 AM EDT - 2 years ago

Prime Medicine Earnings release: Q1 2024


Prime Medicine Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine Proxy statement: Proxy Filing


Prime Medicine Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine Proxy statement: Proxy Filing


Prime Medicine Proxy statement: Proxy Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Prime Medicine Proxy statement: Proxy Filing


Prime Medicine Earnings release: Q4 2023

Mar 1, 2024, 7:00 AM EST - 2 years ago

Prime Medicine Earnings release: Q4 2023


Prime Medicine Annual report: Q4 2023

Mar 1, 2024, 7:00 AM EST - 2 years ago

Prime Medicine Annual report: Q4 2023


Prime Medicine Announces Pricing of Upsized Public Offering

Feb 14, 2024, 11:50 PM EST - 2 years ago

Prime Medicine Announces Pricing of Upsized Public Offering


Prime Medicine Slides: FY 2024

Jan 8, 2024, 5:15 PM EST - 2 years ago

Prime Medicine Slides: FY 2024


Prime Medicine to Present at Upcoming Investor Conferences

Nov 8, 2023, 8:00 AM EST - 2 years ago

Prime Medicine to Present at Upcoming Investor Conferences


Prime Medicine Quarterly report: Q3 2023

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Prime Medicine Quarterly report: Q3 2023


Prime Medicine Earnings release: Q3 2023

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Prime Medicine Earnings release: Q3 2023


Prime Medicine Registration statement: Registration Filing

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Prime Medicine Registration statement: Registration Filing


LadsAndGents
LadsAndGents Jul. 9 at 10:15 PM
$PRME timely exit total in 4.60s, I want to get in if it dips bit more, at the same time they don’t have cash before next big news, could see dilution? Should I wait out ? $XBI anyone chime in?
1 · Reply
Farorm
Farorm Jul. 9 at 7:53 PM
$PRME congrats market nobody is bullish anymore!
0 · Reply
srost002
srost002 Jul. 9 at 7:35 PM
$PRME lol cant make this shit up. Xbi holding bro, wrong direction
1 · Reply
Floorguy7
Floorguy7 Jul. 9 at 6:58 PM
0 · Reply
Farorm
Farorm Jul. 9 at 6:48 PM
$PRME I smell algos hunting your stops ❤️‍🔥
1 · Reply
Floorguy7
Floorguy7 Jul. 9 at 6:01 PM
$PRME how about a quick drop to 4:20…
1 · Reply
Hopipaytrader
Hopipaytrader Jul. 9 at 4:43 PM
$PRME this one’s gonna get angry someday
0 · Reply
Floorguy7
Floorguy7 Jul. 9 at 4:12 PM
$PRME sniff sniff you smell that… opportunity
0 · Reply
PorkchopSquats
PorkchopSquats Jul. 9 at 9:33 AM
$PRME Thank you @Thelonius_Stonk for the horniness.
1 · Reply
BIOTECH_GURU
BIOTECH_GURU Jul. 9 at 3:23 AM
$TERN $ALMS $PRME $ALT $CAPR Alright folks. You saw AlMS, TERN and CApR MAKE WILD RUNS IN 8 MONTHS. get ready for the next runs. $PRME Just formed a golden cross. Won huge legal battle which had a lot of overhang and drove price from upper teens to below $3. Continues to be the highest asymetric play in gene editing as the technology is the cleanest. In human proof of concept is already proven and published. This will make those with high conviction big gains. $ALT all the waiting will be paying off within the next 6 months. $CAPR dropped back down to let me buy the dip. 60 dollars PT. Nfa Gltya.
0 · Reply
NasdaqAlpha
NasdaqAlpha Jul. 8 at 8:57 PM
$PRME won binding arbitration vs $BEAM and kept exclusive rights to PM647. No breach penalties, all claims dismissed. PM647 targets the SERPINA1 mutation with a liver-focused LNP approach and has shown it can restore functional M-AAT protein. Big legal + pipeline win.
0 · Reply
FredGS
FredGS Jul. 8 at 8:51 PM
$PRME Well, Allen has some new things to talk about at the next fireside chat.
0 · Reply
StockEnginee1
StockEnginee1 Jul. 8 at 8:27 PM
$PRME strong headline for bulls, but this is still a hold-and-watch setup. If momentum sticks and volume confirms, the tape can keep pushing higher. Needs follow-through, not just a pop.
0 · Reply
topstockalerts
topstockalerts Jul. 8 at 8:11 PM
Beam Therapeutics shares came under pressure after reports that an arbitration panel ruled in favor of rival Prime Medicine in a dispute over development rights for PM647, an experimental gene-editing therapy targeting alpha-1 antitrypsin deficiency (AATD). The panel found that PM647 falls within Prime Medicine's licensed rights under a 2019 collaboration agreement, dealing a setback to Beam because AATD is also the focus of its lead candidate BEAM-302. The ruling comes after Beam recently reached a fresh 52-week high, supported by a bullish H.C. Wainwright rating and continued progress toward a biologics license application for risto-cel in sickle cell disease. The arbitration outcome introduces new intellectual property and competitive risks around Beam's AATD franchise, prompting investors to reassess the stock's outlook. $BEAM $PRME
0 · Reply
WallStreetGrowth
WallStreetGrowth Jul. 8 at 7:05 PM
$PRME won the BEAM arbitration, and that matters. The tribunal ruled PM647 is inside the licensed field under the 2019 deal, clearing the path for the program. Stock reacted fast, up ~17%. Legal overhang eased, and the market is now pricing in a cleaner setup for the gene-editing pipeline.
0 · Reply
Imwet
Imwet Jul. 8 at 6:23 PM
$PRME closing under 4.50
0 · Reply
YouVSYou
YouVSYou Jul. 8 at 6:20 PM
Daily test here $PRME 4.70 5.47 above Downside Retest 4.27/4.66
0 · Reply
FredGS
FredGS Jul. 8 at 6:16 PM
$PRME Maybe this ruling was bigger than I thought.
0 · Reply
PorkchopSquats
PorkchopSquats Jul. 8 at 6:14 PM
$PRME Blew right through that with almost 2 hours left. Currently 2nd highest volume of all time. Would need an extra 7.5M to take the top spot though, so doubting we see that unless shorts decided to close today rather than risk tomorrow.
0 · Reply
IgotOptionsHere
IgotOptionsHere Jul. 8 at 6:06 PM
$PRME $ORCL $AVAV $EQX $NEXT I call this the great rotation portfolio. Genetic medicine Hyperscalers Autonomous Drones Gold miners LNG Exports Buckle up!
0 · Reply
Lawneverchase
Lawneverchase Jul. 8 at 6:02 PM
$PRME 👀
0 · Reply
Blankbeanie
Blankbeanie Jul. 8 at 6:02 PM
$PRME going for the double tit ride Hand tight
0 · Reply